Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

Niyomnaitham, Suvimol; Toh, Zheng Quan; Wongprompitak, Patimaporn; Jansarikit, Laddawan; Srisutthisamphan, Kanjana; Sapsutthipas, Sompong; Jantraphakorn, Yuparat; Mingngamsup, Natthakarn; Licciardi, Paul V.; Chokephaibulkit, Kulkanya

doi:10.1101/2022.03.03.22271601

Cited by 3 publications

(5 citation statements)

References 34 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, as observed in other studies, homologous and heterologous fractional ID regimens were well-tolerated, with low incidences of systemic AEs and no severe local reactions ( 2 , 15 , 21 ). This was especially evident after the second dose ( 22 ).…”

Section: Discussionsupporting

confidence: 80%

“…Endpoints of AEs were presented as frequencies and Chi-square tests were used to test for statistical differences between endpoints. We represented this information as GMs of anti-RBD-IgG and AE frequency, similar to another report of ours regarding IM regimens in healthy volunteers ( 15 ).…”

Section: Methodsmentioning

confidence: 77%

“…(A) SARS-CoV-2 RBD IgG at baseline, 1 week after the first dose, and 2 weeks after the second dose for Groups 1 to 4, as well as 12 weeks after the second dose for Groups 1 and 2. The reference bars represent the results for conventional intramuscular (IM) routes of each respective COVID-19 vaccine regimen, as obtained from a previous study ( 15 ). (B) Pseudovirus neutralization tests (PVNT 50 , shown in dark blue) and percent seroconversion (shown in blue bars) 2 weeks after the second dose.…”

Section: Resultsmentioning

confidence: 99%

“…(A) Illustrates the systemic reactions and (B) local effects. AEs of conventional intramuscular (IM) administration for each vaccine regimen are included as references from our previous study ( 15 ).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionThis phase I study explored the immunogenicity and reactogenicity of accelerated, Q7 fractional, intradermal vaccination regimens for COVID-19.MethodsParticipants (n = 60) aged 18-60 years, naïve to SARS-CoV-2 infection or vaccination, were randomly allocated into one of four homologous or heterologous accelerated two-dose, two-injection intradermal regimens seven days apart:(1) BNT162b2-BNT162b2(n= 20),(2) ChAdOx1- BNT162b2 (n = 20), (3) CoronaVac-ChAdOx1 (n = 10), and (4) ChAdOx1-ChAdOx1 (n = 10). CoronaVac and ChAdOx1 were 20%, and BNT162b2 17%, of their standard intramuscular doses (0.1 mL and 0.05 mL per injection, respectively). Humoral immune responses were measured through IgG response towards receptor binding domains (RBD-IgG) of ancestral SARS-CoV-2 spike protein and pseudovirus neutralization tests (PVNT50). Cellular immune responses were measured using ELISpot for ancestral protein pools.ResultsImmunogenicity was highest in regimen (2), followed by (1), (4), and (3) 2 weeks after the second dose (P < 0.001 for anti-RBD-IgG and P= 0.01 for PVNT50). Each group had significantly lower anti-RBD IgG (by factors of 5.4, 3.6, 11.6, and 2.0 for regimens (1) to (4), respectively) compared to their respective standard intramuscular regimens (P < 0.001 for each). Seroconversion rates for PVNT50 against the ancestral strain were 75%, 90%, 57% and 37% for regimens (1) to (4), respectively. All participants elicited ELISpot response to S-protein after vaccination. Adverse events were reportedly mild or moderate across cohorts.DiscussionWe concluded that accelerated, fractional, heterologous or homologous intradermal vaccination regimens of BNT162b2 and ChAdOx1 were well tolerated, provided rapid immune priming against SARS-CoV-2, and may prove useful for containing future outbreaks.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Methodsmentioning

confidence: 77%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Encouragingly, T-cell reactivity against variants of concern appears preserved in most vaccinated individuals, with most CD4 and CD8 epitopes conserved across variants [33] , [47] . Inactivated vaccines induce low levels of cellular immunity, but heterologous primary vaccine schedules, including those involving combinations of CoronaVac, ChAdOx1 and BNT162b2, induce high levels of IFN-γ–expressing SARS-CoV-2-specific T-cells [49] . Heterologous boosting with Ad26.COV2.S substantially increased anti-S CD8 + T-cells after primary vaccination with BNT162b2 [44] .…”

Section: Discussionmentioning

confidence: 99%

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

Muangnoicharoen

Wiangcharoen

Nanthapisal

et al. 2023

Vaccine

View full text Add to dashboard Cite

A third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens

Guibert

Trepat

Pozzetto

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: To cope with the persistence of the Covid-19 epidemic and the decrease in antibody levels following vaccination, a third dose of vaccine has been recommended in the general population. However, several vaccine regimens had been used initially, and the heterologous ChadOx1-S/BNT162b2 regimen had shown better efficacy and immunogenicity than the homologous BNT162b2/BNT162b2 regimen. Aim : We wanted to determine if this benefit was retained after the third dose. Methods: We combined an observational study of SARS-COV-2 infections among vaccinated healthcare workers at the University-Hospital of Lyon, France, with an analysis of immunological parameters before and after the third mRNA vaccine dose. Results: Following the second vaccine dose, heterologous vaccination regimens were more protective against infection than homologous regimens, but this was no longer the case after the third dose. RBD-specific IgG levels and serum neutralization capacity against different SARS-CoV-2 variants were higher after the third dose than after the second dose in the homologous regimen group, but not in the heterologous group. Conclusion: The advantage conferred by heterologous vaccination is lost after the third dose in terms of both protection and immunogenicity. Immunological measurements one month after vaccination suggest that heterologous vaccination induces maximal immunity after the second dose, whereas the third dose is required to reach the same level in individuals with a homologous regimen.

show abstract

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

Cited by 3 publications

References 34 publications

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

A third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens

Contact Info

Product

Resources

About